Measuring IL-41 levels in ankylosing spondylitis and psoriatic arthritis
Part of Bones, joints & muscles, Skin clinical trials.
This study looks at the level of a protein called IL-41 in the blood of people with ankylosing spondylitis or psoriatic arthritis, compared to healthy people. The goal is to see if this protein could be used as a marker to help understand or diagnose these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of ankylosing spondylitis or psoriatic arthritis.
- You should not have other autoimmune diseases, diabetes, chronic kidney or liver disease, active infection, or cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a protein called interleukin-33 in people with ankylosing spondylitis (a type of arthritis affecting the spine) and whether it is linked to early signs of heart disease. It aims to find out if this protein could help predict heart problems in people with this condition.
This study looks at the levels of a specific enzyme (15-hydroxyprostaglandin dehydrogenase) in the blood and joints of people with osteoarthritis or ankylosing spondylitis. The goal is to see if this enzyme can help tell these conditions apart or show how active they are.
This study looks at a specific white blood cell (called neutrophils) in people with ankylosing spondylitis. By measuring a marker called Tim-3 on these cells, researchers hope to learn more about the disease, which could help improve future treatments.
This study looks at how inflammatory “cytokines” are expressed in people with psoriasis—both those with joint involvement and those without. It may help researchers understand what drives joint disease and guide better future monitoring or treatments.
This study is looking for people with ankylosing spondylitis, rheumatoid arthritis, or lupus to help find biomarkers that may make diagnosis easier. If you have one of these conditions and haven't tried biologic therapies, you may be able to join.
This study compares two types of biologic drugs (IL-17 inhibitors vs. anti-TNF drugs) in people with ankylosing spondylitis (a form of arthritis affecting the spine) who have already tried standard treatments. The goal is to see which drug works better for controlling symptoms.
Hear when a new Ankylosing Spondylitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.